Description

• Title:
  Efficacy and safety of fenfluramine in the treatment of Dravet syndrome - literature review
• Creator:
  Stefaniak, Martyna;
  Pietrzak, Zofia;
  Dzikowski, Piotr;
  Nowicka, Emilia;
  Obel, Michał;
  Piecewicz-Szczęsna, Halina
• Description:
  Dravet Syndrome is a severe, drug-resistant, and rare epileptiform disorder that is typically presented in the first year of life in an otherwise healthy child. It is characterized by prolonged seizures that are often resistant to current anti-epileptic drug regimens, which made them poorly controlled, and almost 50% of patients experience at least four tonic-clonic seizures per month. There are three new medicines: stiripentol, cannabidiol, and fenfluramine, with documented efficacy and safety as adjunctive therapies in pharmacoresistant Dravet syndrome treatment. This study aimed to assess the efficacy and safety of fenfluramine in the treatment of Dravet syndrome. Our study material consisted of publications, which were found in PubMed, Google Scholar, and Embase databases. In order to find the proper publications, the search has been conducted with the use of a combination of keywords like: “fenfluramine”, “Dravet syndrome”, “epilepsy treatment”, “Dravet syndrome pediatric patients”. The first step was to find proper publications from the last 10 years. The second step was to carry out an overview of the found publications. Results of mentioned studies proved that in Dravet syndrome, fenfluramine provided a significantly greater reduction in convulsive seizure frequency compared with placebo. No patient developed valvular heart disease or pulmonary arterial hypertension, the side effects that occurred during its use were mild and the drug was generally well-tolerated. The bioequivalence and tolerability of single oral doses of fenfluramine hydrochloride oral solution in the fed and fasted states support drug administration without regard to meals. Fenfluramine may represent a new important treatment option for Dravet syndrome.
• Object availability:
  free access
• Rights:
  Prawa autorskie (c) 2022 Martyna Stefaniak, Zofia Pietrzak, Piotr Dzikowski, Emilia Nowicka, Michał Obel, Halina Piecewicz-Szczęsna;
  http://creativecommons.org/licenses/by-nc-sa/4.0
• Date:
  2022.01.14
• Type:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Language:
  English
• Source:
  Journal of Education, Health and Sport; Vol. 12 No. 1 (2022); 106-116;
  Journal of Education, Health and Sport; Tom 12 Nr 1 (2022); 106-116;
  2391-8306
• Format:
  application/pdf
• Publisher:
  Nicolaus Copernicus University, Toruń, Poland
• Relation: https://apcz.umk.pl/JEHS/article/view/37106/31434
• Subject:
  fenfluramine;
  Dravet syndrome;
  epilepsy treatment;
  seizure frequency;
  pharmacokinetics
• Identifier: https://apcz.umk.pl/JEHS/article/view/37106
• Data provider:
  Akademicka Platforma Czasopism
• Can I use it?:
  seek permission
• Type:
  text